Lawrence Mehren Net Worth

The estimated Net Worth of Lawrence Mehren is at least $13.8 Milion dollars as of 17 August 2017. Lawrence Mehren owns over 223,215 units of Accelerate Diagnostics Inc stock worth over $1,227,433 and over the last 12 years Lawrence sold AXDX stock worth over $12,601,308.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lawrence Mehren AXDX stock SEC Form 4 insiders trading

Lawrence has made over 3 trades of the Accelerate Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Lawrence sold 223,215 units of AXDX stock worth $5,000,016 on 17 August 2017.

The largest trade Lawrence's ever made was selling 400,068 units of Accelerate Diagnostics Inc stock on 9 January 2017 worth over $7,601,292. On average, Lawrence trades about 62,378 units every 88 days since 2013. As of 17 August 2017 Lawrence still owns at least 762,381 units of Accelerate Diagnostics Inc stock.

You can see the complete history of Lawrence Mehren stock trades at the bottom of the page.

What's Lawrence Mehren's mailing address?

Lawrence's mailing address filed with the SEC is 5661 NORTH CALLE MAYAPAN, , TUCSON, AZ, 85718.

Insiders trading at Accelerate Diagnostics Inc

Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg a Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.

What does Accelerate Diagnostics Inc do?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Complete history of Lawrence Mehren stock trades at Accelerate Diagnostics Inc

Accelerate Diagnostics Inc executives and stock owners

Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Phillips,
  Chief Executive Officer, Chief Operating Officer, Director
• Steve Reichling,
  Chief Financial Officer
• Jack Phillips,
  CEO, Pres & Director
• Ron Price,
  Senior Vice President, Head of Commercial Operations, Americas
• Roland Diggelmann,
  Independent Director
• Louise Francesconi,
  Independent Director
• Steve Reichling,
  CFO & Chief Accounting Officer
• Ron Price,
  Chief Commercial Officer of Americas
• Charles Watts,
  Independent Director
• Frank ten Brink,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Jack Schuler,
  Independent Director
• Mark Miller,
  Independent Director
• Thomas Brown,
  Independent Director
• John Patience,
  Independent Chairman of the Board
• Nedal Safwat,
  Chief Strategy Officer
• Dr. Lawrence Mertz,
  Sr. VP and Head of R&D
• John Meduri,
  Chief Strategy Officer
• Laura Costa,
  Sr. VP & Head of Global Customer Support
• Cherif Bousselham,
  Sr. VP & Head of Sales - EMEA
• Gretchen Strohminger,
  Sr. VP and Head of HR & Culture
• Michael Bridge,
  Sr. VP, Gen. Counsel & Sec.
• Laura Pierson,
  Investor Relations Officer
• Larry N Feinberg,
  10% owner
• Pete Bantock,
  CHIEF COMMERCIAL OFFICER
• Lawrence Mehren,
  PRESIDENT AND CEO
• Marran H. Ogilvie,
  Director
• Jennifer Regan,
  Director
• Mark S. Black,
  Director
• Ventures, Llc Abeja,
  10% owner
• Romney Humphries,
  Chief Scientific Officer
• Larry Michael Mertz,
  Chief Technology Officer
• Hany Massarany,
  Director
• Jack Phillips,
  Chief Executive Officer
• Wayne Burris,
  Director
• David Patience,
  Chief Financial Officer